ORIC
What one share of Oric Pharmaceuticals holds
Pharmaceutical Preparations
Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments.
Oric Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.35 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.08 |
| Cash and investments | $0.36 |
| Book value | $3.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$12.32 | $0.30 | −$12.23 | — | −$37.15 |
| 2019 | — | −$14.15 | $0.40 | −$12.79 | — | −$45.40 |
| 2020 | — | −$3.36 | $0.03 | −$2.09 | — | $7.90 |
| 2021 | — | −$2.07 | $0.02 | −$1.59 | — | $6.92 |
| 2022 | — | −$2.25 | $0.05 | −$1.95 | — | $4.93 |
| 2023 | — | −$1.96 | $0.02 | −$1.68 | — | $4.08 |
| 2024 | — | −$1.83 | $0.02 | −$1.63 | — | $3.42 |
| 2025 | — | −$1.47 | $0.01 | −$1.27 | — | $3.90 |